Clinical safety evaluation of Endeavor stent in octogenerians. - E-OCTO Registry

Cardiovascular center, Shinkawabashi hospital0 个研究点目标入组 200 人开始时间: 2010年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Limited Life expectancy within 12months. 2)Inability to comply with the required IFU antiplatelet regimen. 3)Ejection Fraction<30%. 4)Unprotected LMT disease. 5)Chronic Total Occulution. 6)The lesions in all native coronary arteries, LCX/LAD/RCA should be amenable to PCI. 7)Severe valvular disease. 8)Renal Failure. 9)Taking Warfarin Potassium. 10)Planed PCI of any vessel within 30 days post-index procedure and/or planed PCI of the target vessel(s) within 12 months post-procedure. 11)Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel and ticlopidine, cobalt, nickel, chromium, molybdenum, polymer coating (e.g.PC polymer) or a sensitivity to contrast media, which cannot be adequately pre-medicated. 12)Acute myocardial infaction with cardogenic shock. 13)Previous stenting in the target vessel(s). 14)Prior to enrollment in this study, if a surgical or any procedure is anticipated that would require early discontinuation of 3-month antiplatelet therapy. 15)Patient is not an acceptable candidate for PCI at a physician's discretion.

发起方

Cardiovascular center, Shinkawabashi hospital